AC Immune S.A.
AC Immune S.A. (ACIU) Revenue
Annual & quarterly revenue history · segment & region breakdown
ACIU · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAC Immune S.A. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 86.92% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.02B | -86.92% |
| 2024-12-31 | $0.03B | +$0.01B | +84.51% |
| 2023-12-31 | $0.01B | +$0.01B | +276.14% |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.02B | -100.00% |
| 2020-12-31 | $0.02B | -$0.10B | -86.03% |
| 2019-12-31 | $0.11B | +$0.10B | +1435.39% |
| 2018-12-31 | $0.01B | -$0.01B | -64.48% |
| 2017-12-31 | $0.02B | -$0.00B | -12.75% |
| 2016-12-31 | $0.02B | -$0.02B | -40.61% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income AC Immune S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
AC Immune S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CHF.
Data sourced from AC Immune S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ACIU revenue · 4 questionsACIU's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 86.92% year-over-year from $0.00B in FY2025.
▸ Source: FMP · AC Immune S.A. SEC filings · GAAP · AC Immune S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026